67. 多発性嚢胞腎 Polycystic kidney disease Clinical trials / Disease details

臨床試験数 : 221 / 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151

10 trials found

diseases per page:

Showing 1 to 10 of 10 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01670110 (ClinicalTrials.gov)	August 2012	17/8/2012	Pasireotide LAR in Severe Polycystic Liver Disease	A Randomized, Placebo Controlled Clinical Trial of SOM230 (Pasireotide LAR) In Severe Polycystic Liv ...	SomatostatinAnalogs;Polycystic Liver Disease;Autosomal Dominant Polycystic Kidney Disease;Autosomal ...	Drug: Pasireotide LAR;Drug: Placebo	Mayo Clinic	NULL	Completed	18 Years	100 Years	All	48	Phase 2	United States
2	NCT01354405 (ClinicalTrials.gov)	May 2011	13/5/2011	Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)	The Effect of Lanreotide on Volume of Polycystic Liver and Kidney in Autosomal Dominant Polycystic K ...	Polycystic Liver Disease	Drug: Lanreotide	Radboud University	Ipsen	Completed	18 Years	70 Years	Both	43	N/A	Netherlands
3	NCT01377246 (ClinicalTrials.gov)	May 2011	20/6/2011	SomatostatinIn Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Ren ...	A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO ASSESS THE EFFECTS OF ...	Autosomal Dominant Polycystic Kidney Disease	Drug: Octreotide -LAR;Other: Saline solution.	Mario Negri Institute for Pharmacological Research	NULL	Completed	18 Years	75 Years	All	100	Phase 3	Italy
4	EUCTR2011-000138-12-IT (EUCTR)	04/04/2011	28/12/2011	A prospective, randomized, double-blind, placebo controlled clinical trial to assess the effects of ...	A prospective, randomized, double-blind, placebo controlled clinical trial to assess the effects of ...	Autosomal Dominant Polycystic Kidney Disease MedDRA version: 14.1;Level: LLT;Classification code 100 ...	Trade Name: SANDOSTATINA LAR INN or Proposed INN: Octreotide	IST. DI RICERCHE FARMACOLOG. M. NEGRI	NULL	Not Recruiting			Female: yes Male: yes	80	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Italy
5	EUCTR2009-017849-57-NL (EUCTR)	24/03/2011	13/01/2010	Somatostatin analogues as a volume reducing treatment of polycystic livers - SOLVE	Somatostatin analogues as a volume reducing treatment of polycystic livers - SOLVE	Polycystic liver disease, due to isolated polycystic liver disease or polycystic kidney disease. Med ...	Product Name: Sandostatin LAR Product Code: unknown Product Name: Somatuline Autosolution Product Code: ...	Radboud University Nijmegen Medical Centre	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 4	Netherlands
6	EUCTR2009-012376-27-IT (EUCTR)	16/11/2009	30/11/2009	EFFECTS OF LONG-ACTING SOMATOSTATINON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCY ...	EFFECTS OF LONG-ACTING SOMATOSTATINON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCY ...	Polycystic Kidney MedDRA version: 12.1;Level: LLT;Classification code 10036046;Term: Polycystic kidn ...	Trade Name: SANDOSTATINA LAR INN or Proposed INN: Octreotide	IST. DI RICERCHE FARMACOLOG. M. NEGRI	NULL	Not Recruiting			Female: yes Male: yes	80	Phase 3	Italy
7	NCT02119013 (ClinicalTrials.gov)	January 2009	17/4/2014	Effects of Somatostatin on ADPKD Heart	EFFECT OF SOMATOSTTIN ON EARLY DIASTOLIC LEFT VENTRICULAR FUNCTION IN AUTOSOMAL DOMINANT POLYCYSTIC ...	Autosomal Dominant Polycystic Kidney Disease;Glomerular Filtration Rate > 40 ml/Min	Drug: Octeotride;Drug: Placebo	Federico II University	NULL	Completed	18 Years	80 Years	Both	35	Phase 2/Phase 3	NULL
8	NCT02119052 (ClinicalTrials.gov)	January 2009	17/4/2014	Effects of Somatostatin on Liver in ADPKD	Effect of Long-acting Somatostatin on Liver in Autosomal Dominant Polycystic Kidney Disease	Autosomal Dominant Polycystic Kidney Disease	Drug: octeotride;Drug: placebo	Federico II University	NULL	Completed	18 Years	N/A	Both	35	Phase 2/Phase 3	NULL
9	NCT00309283 (ClinicalTrials.gov)	April 2006	30/3/2006	Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study	Effect of a Long-acting Somatostatinon Disease Progression in Nephropathy Due to Autosomal Dominant ...	Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Drug: Long-acting somatostatin;Other: Saline solution	Mario Negri Institute for Pharmacological Research	NULL	Completed	18 Years	75 Years	Both	78	Phase 3	Italy
10	EUCTR2005-005552-41-IT (EUCTR)	20/02/2006	06/03/2007	Effect of long-acting somatostatinon disease progression in nephropathy due to autosomal dominant po ...	Effect of long-acting somatostatinon disease progression in nephropathy due to autosomal dominant po ...	Autosomal Dominant Polycystic Kidney Disease ADPKD MedDRA version: 6.1;Level: SOC;Classification cod ...	Trade Name: Sandostatina Lar IM Fl 20mg +2F Product Name: octreotide INN or Proposed INN: Octreotide	IST. DI RICERCHE FARMACOLOG. M. NEGRI	NULL	Not Recruiting			Female: yes Male: yes	66	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Italy

First Previous1Next Last